Home

Eli Lilly (LLY)

1,075.47
-28.87 (-2.61%)
NYSE · Last Trade: Nov 28th, 4:11 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Top S&P500 movers in Friday's sessionchartmill.com
Let's delve into the developments on the US markets one hour before the close of the markets on Friday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Via Chartmill · November 28, 2025
Beyond the Giants: Gauging Emerging Large-Cap Leadership Amidst Broadening Market Dynamics
The financial markets in late 2025 are signaling a significant, albeit cautious, shift away from the concentrated leadership that has defined much of the past two years. For an extended period, market gains were predominantly driven by a select cohort of mega-cap technology companies, often dubbed the "Magnificent Seven," largely
Via MarketMinute · November 28, 2025
These S&P500 stocks are moving in today's sessionchartmill.com
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Friday.
Via Chartmill · November 28, 2025
Eli Lilly Unusual Options Activitybenzinga.com
Via Benzinga · November 28, 2025
Gapping S&P500 stocks in Friday's sessionchartmill.com
Curious about the S&P500 stocks that are gapping on Friday? Explore the gap up and gap down stocks in the S&P500 index during today's session.
Via Chartmill · November 28, 2025
Is Johnson & Johnson Stock Outperforming the S&P 500?
Johnson & Johnson has outpaced the S&P 500 over the past year, and analysts remain optimistic about the healthcare stock's growth potential ahead.
Via Barchart.com · November 28, 2025
Prediction: This Undervalued Stock Could Compete With Novo Nordisk by 2029fool.com
The mid-cap biotech could become a notable player in the industry's hottest therapeutic area.
Via The Motley Fool · November 27, 2025
Prediction: This Growth Stock Could Hit a $2 Trillion Valuation by 2031fool.com
It's not only tech companies that can get to that market valuation.
Via The Motley Fool · November 27, 2025
Eli Lilly’s Stock Price Has Fattened Up Like a Thanksgiving Turkey. Time to (Options) Collar That Green!
As Eli Lilly makes history by joining the $1 trillion club, here’s how you can position for its next move.
Via Barchart.com · November 27, 2025
JPMorgan Says 2027 Medicare Drug Prices Signal Up To 40% Cuts Ahead — Novo Nordisk And Teva Stand Out As Top Targetsstocktwits.com
JPMorgan said the implied net impact aligns with recent commentary from Novo Nordisk, Teva and AbbVie during earnings season.
Via Stocktwits · November 26, 2025
Stock Split Watch: Is Eli Lilly Next?fool.com
The stock recently reached beyond $1,000.
Via The Motley Fool · November 26, 2025
U.S. Stocks Extend Winning Streak as Wall Street Bets on Dovish Fed Pivot
New York, NY – November 26, 2025 – U.S. stock markets are surging, with Wall Street poised to extend a remarkable winning streak as investors enthusiastically price in aggressive interest rate cuts by the Federal Reserve. This newfound optimism, particularly evident in the days leading up to November 26, 2025, has
Via MarketMinute · November 26, 2025
Is AbbVie Stock Outperforming the Nasdaq?
AbbVie has outperformed the Nasdaq over the past year, and analysts are moderately optimistic about the stock’s prospects.
Via Barchart.com · November 26, 2025
Could AI Infrastructure Spending Be the Next Gold Rush for Investors?fool.com
Companies and investors see AI as a game-changing technology.
Via The Motley Fool · November 26, 2025
Did Pfizer Just Say "Checkmate" to Novo Nordisk?fool.com
The weight loss drug market may approach almost $100 billion by the end of the decade.
Via The Motley Fool · November 26, 2025
Retail Traders Crown Novo Nordisk As Long-Term Weight Loss King — Even As Eli Lilly Hits $1T And Viking Fans Tout ‘M&A Prize’stocktwits.com
Users pointed to emerging drug pipelines, GLP-1 expansion and rising M&A pressure across the sector.
Via Stocktwits · November 25, 2025
Q3 Rundown: Organon (NYSE:OGN) Vs Other Branded Pharmaceuticals Stocks
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Organon (NYSE:OGN) and its peers.
Via StockStory · November 25, 2025
Should You Buy the Massive Dip in Novo Nordisk Stock?
Novo’s failed Alzheimer’s bet sparked a sharp selloff, leaving investors debating whether this bruising dip is a bargain or not.
Via Barchart.com · November 25, 2025
Here's Why Novo Nordisk Stock Popped Todayfool.com
Good news from a GLP-1 receptor agonist clinical trial hit the market today.
Via The Motley Fool · November 25, 2025
The Great Divide: Is the Market Offering a Dip or Signalling a Bear?
As November 25, 2025, unfolds, financial markets find themselves at a critical juncture, gripped by a pervasive debate that pits optimists against skeptics: are current market pullbacks merely a "Buy The Dip" opportunity, or do they herald the onset of a more protracted "Bear Market"? This question hangs heavy in
Via MarketMinute · November 25, 2025
Is UnitedHealth Group Stock Underperforming the Nasdaq?
Though UnitedHealth Group has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.
Via Barchart.com · November 25, 2025
A Trillion-Dollar Pill: Eli Lilly Broke the Healthcare Ceilingmarketbeat.com
Via MarketBeat · November 25, 2025
How Is Eli Lilly’s Stock Performance Compared to Other Pharmaceuticals?
Eli Lilly’s remarkable outperformance within the pharmaceutical sector hasn’t tempered enthusiasm, analysts are still strongly bullish on its long-term growth potential.
Via Barchart.com · November 25, 2025
This Healthcare Company Just Touched $1 Trillion in Market Cap. Should You Invest $1,000?fool.com
The rapidly expanding market for GLP-1 drugs has added massively to Eli Lilly's market cap.
Via The Motley Fool · November 24, 2025
Novo Nordisk's Stock Slump Shows The GLP‑1 Trade's Side Effect: ETF Concentration Riskbenzinga.com
Novo's trial setback tests GLP-1-heavy ETFs, highlighting concentration risks while Eli Lilly's diversified pipeline offers relative resilience.
Via Benzinga · November 24, 2025